TTOO Insider Trading
T2 Biosystems, Inc. | Surgical & Medical Instruments & Apparatus
Comprehensive Trading Performance Summary
The investment history of corporate insiders at T2 Biosystems, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Surgical & Medical Instruments & Apparatus sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-18 00:00 | 2024-09-13 | Elsbree David B | Director | SELL | $2.42 | 55 | $133 | 23 | -70.5% |
| 2023-11-29 00:00 | 2023-02-20 | Giffin Brett A. | Officer - Chief Commercial Officer | OPT+S | $0.65 | 537 | $349 | 3,049 | 0.0% |
| 2023-09-29 23:30 | 2023-09-27 | CR Group L.P. | 10% owner | SELL | $0.17 | 13,130,147 | $2,271,515 | 0 | -100.0% |
| 2023-09-28 23:30 | 2023-09-26 | CR Group L.P. | 10% owner | SELL | $0.20 | 5,392,920 | $1,082,359 | 3,559,165 | -60.2% |
| 2023-09-28 00:53 | 2023-09-25 | CR Group L.P. | 10% owner | SELL | $0.25 | 250,000 | $62,500 | 5,021,014 | -4.7% |
| 2023-09-27 00:15 | 2023-09-22 | CR Group L.P. | 10% owner | SELL | $0.26 | 5,079,344 | $1,314,534 | 5,088,781 | -50.0% |
| 2023-09-26 03:30 | 2023-09-21 | CR Group L.P. | 10% owner | SELL | $0.30 | 6,338,211 | $1,904,632 | 6,465,629 | -49.5% |
| 2023-09-22 23:15 | 2023-09-20 | CR Group L.P. | 10% owner | SELL | $0.31 | 7,753,710 | $2,408,302 | 8,183,716 | -48.7% |
| 2023-09-21 23:30 | 2023-09-19 | CR Group L.P. | 10% owner | SELL | $0.37 | 10,401,466 | $3,806,937 | 10,285,500 | -50.3% |
| 2023-04-06 20:08 | 2023-03-28 | Gibbs Michael Terrence | Officer - General Counsel | SELL | $0.48 | 239 | $115 | 6,612 | -3.5% |
| 2023-03-10 00:00 | 2023-02-22 | Giffin Brett A. | Officer - Chief Commercial Officer | OPT+S | $0.65 | 537 | $349 | 841 | 0.0% |
| 2023-03-10 00:00 | 2023-02-22 | Sprague John M | Officer - Chief Financial Officer | OPT+S | $0.62 | 2,693 | $1,682 | 7,268 | 0.0% |
| 2023-03-10 00:00 | 2023-02-22 | Gibbs Michael Terrence | Officer - General Counsel | OPT+S | $0.62 | 3,730 | $2,329 | 6,517 | 0.0% |
| 2023-03-10 00:00 | 2023-02-22 | Sperzel John J III | Director, Officer - Chairman and CEO | OPT+S | $0.63 | 9,773 | $6,178 | 17,329 | 0.0% |
| 2022-11-23 00:00 | 2022-11-10 | Giffin Brett A. | Officer - Chief Commercial Officer | OPT+S | $1.79 | 1,292 | $2,317 | 2,253 | 0.0% |
| 2022-04-11 17:07 | 2022-04-07 | Sperzel John J III | Director, Officer - Chairman, CEO, and President | BUY | $0.50 | 30,000 | $15,000 | 221,773 | +15.6% |
| 2022-04-11 16:55 | 2022-04-08 | Barclay Alec | Officer - Chief Operations Officer | BUY | $0.50 | 12,952 | $6,476 | 181,945 | +7.7% |
| 2022-04-11 16:50 | 2022-04-07 | Gibbs Michael Terrence | Officer - General Counsel | BUY | $0.49 | 10,000 | $4,900 | 166,651 | +6.4% |
| 2022-04-11 16:40 | 2022-04-08 | Sprague John M | Officer - Chief Financial Officer | BUY | $0.48 | 10,000 | $4,767 | 152,350 | +7.0% |
| 2022-04-11 16:38 | 2022-04-08 | Giffin Brett A. | Officer - Chief Commercial Officer | BUY | $0.49 | 10,600 | $5,183 | 10,600 | +100.0% |
| 2022-01-11 00:19 | 2022-01-06 | Ahuja Aparna | Officer - Chief Medical Officer | SELL | $0.48 | 61,988 | $29,754 | 107,611 | -36.5% |
| 2021-08-04 01:41 | 2020-03-24 | GOLDMAN SACHS & CO. LLC | 10% owner | BUY | $0.64 | 46,254 | $29,774 | 4,201,582 | +1.1% |
| 2021-08-04 01:41 | 2020-03-24 | GOLDMAN SACHS & CO. LLC | 10% owner | SELL | $0.62 | 41,128 | $25,656 | 4,196,456 | -1.0% |
| 2021-08-04 01:39 | 2020-03-24 | Jones Adrian M | Director | BUY | $0.64 | 46,254 | $29,774 | 4,201,582 | +1.1% |
| 2021-08-04 01:39 | 2020-03-24 | Jones Adrian M | Director | SELL | $0.62 | 41,128 | $25,656 | 4,196,456 | -1.0% |
| 2021-07-02 23:00 | 2021-07-01 | McDonough John | Director | SELL | $1.16 | 18,182 | $21,091 | 516,386 | -3.4% |
| 2021-07-02 23:00 | 2021-07-01 | CUMMING JOHN W | Director | SELL | $1.16 | 18,182 | $21,091 | 50,852 | -26.3% |
| 2021-03-25 22:17 | 2021-03-25 | Gibbs Michael Terrence | Officer - General Counsel | OPT+S | $1.56 | 8,758 | $13,662 | 73,256 | 0.0% |
| 2021-03-18 23:34 | 2021-03-17 | Barclay Alec | Officer - Chief Operations Officer | SELL | $1.86 | 12,494 | $23,239 | 74,420 | -14.4% |
| 2021-03-18 23:34 | 2021-03-17 | Pare Anthony | Officer - Chief Commercial Officer | SELL | $1.84 | 9,620 | $17,701 | 31,612 | -23.3% |
| 2021-02-23 22:23 | 2021-02-23 | Gibbs Michael Terrence | Officer - General Counsel | OPT+S | $2.06 | 7,280 | $14,997 | 65,347 | 0.0% |
| 2021-02-23 22:19 | 2021-02-23 | Sprague John M | Officer - Chief Financial Officer | OPT+S | $2.04 | 5,250 | $10,710 | 35,485 | 0.0% |
| 2021-02-23 22:14 | 2021-02-23 | Barclay Alec | Officer - Chief Operations Officer | OPT+S | $2.06 | 7,280 | $14,997 | 65,247 | 0.0% |
| 2020-03-03 20:39 | 2020-02-24 | Sprague John M | Officer - Chief Financial Officer | OPT+S | $0.82 | 4,166 | $3,416 | 22,222 | 0.0% |
| 2020-02-26 02:24 | 2020-02-24 | Barclay Alec | Officer - SVP, Operations | OPT+S | $0.82 | 5,808 | $4,763 | 46,294 | 0.0% |
| 2020-02-26 02:22 | 2020-02-24 | Gibbs Michael Terrence | Officer - General Counsel | OPT+S | $0.82 | 5,808 | $4,763 | 60,779 | 0.0% |
| 2020-02-26 02:19 | 2020-02-24 | Lowery Thomas J. | Officer - Chief Scientific Officer | OPT+S | $0.82 | 5,808 | $4,763 | 68,994 | 0.0% |
| 2020-02-13 01:35 | 2020-02-11 | Lowery Thomas J. | Officer - Chief Scientific Officer | OPT+S | $0.77 | 3,200 | $2,464 | 64,802 | 0.0% |
| 2020-02-13 01:31 | 2020-02-11 | Gibbs Michael Terrence | Officer - General Counsel | OPT+S | $0.77 | 3,200 | $2,464 | 56,587 | 0.0% |
| 2020-02-06 01:02 | 2020-02-03 | Gibbs Michael Terrence | Officer - General Counsel | SELL | $0.88 | 3,283 | $2,889 | 53,954 | -5.7% |
| 2020-02-06 01:01 | 2020-02-03 | McDonough John | Director | SELL | $0.88 | 23,754 | $20,904 | 489,114 | -4.6% |
| 2020-02-06 01:01 | 2020-02-03 | Lowery Thomas J. | Officer - Chief Scientific Officer | SELL | $0.88 | 7,535 | $6,631 | 62,169 | -10.8% |
| 2020-01-27 22:58 | 2020-01-23 | McDonough John | Director | SELL | $1.15 | 57,417 | $66,030 | 512,868 | -10.1% |
| 2020-01-07 22:12 | 2020-01-03 | Elsbree David B | Director | SELL | $1.16 | 5,316 | $6,167 | 91,081 | -5.5% |
| 2019-09-13 13:05 | 2019-09-11 | Barclay Alec | Officer - SVP, Operations | OPT+S | $2.92 | 4,210 | $12,293 | 42,102 | 0.0% |
| 2019-06-13 23:31 | 2019-06-11 | Cima Michael J. | Director | SELL | $1.43 | 3,240 | $4,633 | 213,178 | -1.5% |
| 2019-06-13 23:30 | 2019-06-11 | Lapidus Stanley | Director | SELL | $1.44 | 9,000 | $12,960 | 53,010 | -14.5% |
| 2019-06-13 23:30 | 2019-06-11 | CUMMING JOHN W | Director | SELL | $1.43 | 3,420 | $4,891 | 23,580 | -12.7% |
| 2019-06-13 23:30 | 2019-06-11 | Elsbree David B | Director | SELL | $1.44 | 3,600 | $5,184 | 83,108 | -4.2% |
| 2019-02-13 00:52 | 2019-02-11 | Lowery Thomas J. | Officer - Chief Scientific Officer | OPT+S | $3.36 | 3,005 | $10,097 | 69,704 | 0.0% |
How to Interpret $TTOO Trades
Not every insider transaction in T2 Biosystems, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $TTOO shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for TTOO
Insider activity data for T2 Biosystems, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $TTOO, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.